How effective are weight loss interventions for improving fertility in women and men who are overweight or obese? A systematic review and meta-analysis of the evidence.

Authors: Damian Best[1], Alison Avenell[2], Siladitya Bhattacharya[1]

[1]Aberdeen Fertility Centre, University of Aberdeen, Aberdeen, United Kingdom, AB25 2ZL;

[2]Health Services Research Unit, University of Aberdeen Foresterhill, Aberdeen, United Kingdom, AB25 2ZD

Corresponding author Damian Best: dajbest1@gmail.com

Obstetrics & Gynaecology, Faculty of Medical Sciences, University of the West Indies Queen Elizabeth Hospital, St. Michael, Barbados, BB11155.

Running title: Do weight loss interventions improve fertility?

AUTHOR: there is a limit of 50 characters for the running title. Is this alternative acceptable?

Commented [BDA1]: Yes

Style Definition: TOC 1: Font: Not Bold, Do not check spelling or grammar

1

Table of Contents

AUTHOR: the table of contents does not appear to agree with the text. Only first (e.g. **Introduction, Methods**) and second level headings (e.g. ***Criteria for considering studies for this review***) can be included in the Table of Contents (although third etc. level headings are allowed in the main text). The styles used for headings in the main text should be consistent and only second level headers included here. Please would you recheck and edit both the main text and Table of Contents accordingly? Thank you.

46   **Abstract**

47

48   **BACKGROUND**

49   The prevalence of obesity is increasing worldwide, with a corresponding increase in overweight

50   and obese patients referred with infertility. This systematic review aimed to determine whether

51   non-surgical weight reduction strategies result in an improvement in reproductive parameters

52   affected by obesity, e.g. delayed time to pregnancy, oligozoospermia and azoospermia. No prior

53   reviews have examined this within the general fertility population, or in both sexes.

54

55   **OBJECTIVE AND RATIONALE**

56   Our objective was to answer the question: "In overweight and obese women, men and couples

57   seeking fertility treatment, what non-surgical weight loss interventions have been used, and

58   how effective are they at weight loss and improving reproductive outcomes?"

59

60   **SEARCH METHODS**

61   An electronic search of MEDLINE, EMBASE and the Cochrane Library was performed for studies

62   published between (AUTHOR: correct?) January 1966 and March 2016. Text word and MESH

63   search terms used related to infertility, weight, and barriers to weight loss. Inclusion criteria

64   were: an intervention to change lifestyle evaluated in any study design in participants of either

65   gender with an unfulfilled desire to conceive. Studies were excluded if they included

66   participants not attempting pregnancy, with illnesses that might cause weight fluctuations, or

67   studies evaluating bariatric surgery. Two reviewers performed data extraction and quality

Commented [BDA3]: Yes

68 assessment using the Cochrane Risk of Bias Tool for randomised trials, and a ratified checklist

69 (ReBIP) for non-randomised studies.

70

71 **OUTCOMES**

72 A total of 40 studies were included, of which 14 were RCTs. Primary outcomes were pregnancy,

73 live birth rate and weight change. In women, reduced calorie diets and exercise interventions

74 were more likely than control interventions to result in pregnancy [Risk Ratio 1.59, 95% CI

75 (1.01, 2.50)], and interventions resulted in weight loss and ovulation improvement, where

76 reported. Miscarriage rates were not reduced by any intervention.

77

78 **WIDER IMPLICATIONS**

79 Overweight and obese persons seeking fertility should be educated on the detrimental effects of

80 fatness and the benefits of weight reduction, including improvement in pregnancy rates. A

81 combination of a reduced calorie diet, by reducing fat and refined carbohydrate intake, and

82 increased aerobic exercise should form the basis of programmes designed for such individuals.

83 A lack of randomised studies in men and couples, and studies evaluating barriers to undertaking

84 weight loss in infertile populations is evident, and future research should examine these issues

85 further.

86

87 **Key words:** infertility, obesity, weight loss, systematic review, diet, exercise

Introduction

Overweight is defined by the World Health Organization (WHO) (World Health Organization, 2016) as a BMI ≥ 25 kg/m^2, and obesity as ≥ 30 kg/m^2. The prevalence of obesity is increasing worldwide (World Health Organization, 2016), with more than 600 million obese adults, including 15% of women, in 2014 - double the prevalence reported three decades earlier. Infertility is defined by the failure to achieve a clinical pregnancy after 12 months or more of regular unprotected sexual intercourse (Zegers-Hochschild *et al.*, 2009; National Institute for Health and Clinical Excellence, 2013). Using this definition, infertility affects about 1 in 7 couples in the UK, which is similar to an estimate of prevalence in the USA (Thoma *et al.*, 2013). An increasingly overweight and obese population has led to a greater proportion of individuals with high BMI being evaluated in infertility settings (Vahratian and Smith, 2009).

BMI has been associated with delayed conception in women in a dose-dependent fashion (Gesink Law *et al.*, 2007; Wise *et al.*, 2013; Wise *et al.*, 2010). It is thought to produce anovulation (Zain and Norman, 2008; Klenov and Jungheim, 2014), which results in menstrual irregularity (Hartz *et al.*, 1979; Zain and Norman, 2008); impairment of oocyte development (Klenov and Jungheim, 2014) and quality (Carrell *et al.*, 2001; Metwally *et al.*, 2007); and it also has direct effects on the endometrium (Bellver *et al.*, 2011). With ovulation induction (OI) treatment, higher doses of medications (Dickey *et al.*; Balen *et al.*, 2006a) and a longer period of stimulation (Balen *et al.*, 2006b) are required with a higher BMI. With IVF, the chances of achieving a pregnancy decrease with each unit increase in BMI (Ferlitsch *et al.*, 2004), and it is thought that implantation rates are lower in obese women (Bellver *et al.*, 2010; Styne-Gross *et al.*, 2005). An increased risk of miscarriage following IVF has also been reported (Maheshwari *et al.*, 2007).

114　Obesity may affect male fertility in a dose-dependent manner (Sallmen *et al.*, 2006). Postulated

115　mechanisms include increased testicular temperature with prolonged sitting (Hammoud *et al.*,

116　2012), and increased oestrogen production in fat with disruption of the hypothalamo-pituitary-

117　gonadal axis (Schneider *et al.*, 1979; Shukla *et al.*, 2014). Some studies have suggested reduced

118　sperm concentration and motility (Hammiche *et al.*, 2012; Hakonsen *et al.*, 2011; Sermondade

119　*et al.*, 2013), and lower clinical pregnancy rates with IVF (Keltz *et al.*, 2010; Umul *et al.*, 2015)

120　with increasing male adiposity. Where both partners are obese, greater difficulty achieving

121　pregnancy is expected (Ramlau-Hansen *et al.*, 2007).

122

123　Patients attending for fertility treatments are often advised to optimize their weights to

124　improve outcomes, and in some cases to access assistance with funding (National Institute for

125　Health and Clinical Excellence, 2013; Farquhar and Gillett, 2006; Infertility Network UK, 2015)

126　or to reduce the risks of obstetric complications (The Royal Australian and New Zealand College

127　of Obstetricians and Gynaecologists, 2011).

128

129　The purpose of this systematic review was to investigate first whether weight loss interventions

130　for infertile patients achieve their goal in reducing weight, and second whether they result in

131　improved fertility outcomes. A prior systematic review of 11 studies in women (Sim K.A. *et al.*,

132　2014) focussed on assisted reproduction only and used a much more limited search for studies

133　up until 2014. Our review used an extensive search until 2016 and presents data from 40

134　studies with women and men with infertility, not just patients requiring assisted reproduction.

135

Methods

This systematic review was undertaken according to a pre-specified protocol.

Criteria for considering studies for this review

Types of studies

We included intervention studies in overweight or obese participants with any design and any duration of follow-up.

Types of participants

Participants could be of either sex. They were required to have both infertility, defined by an unfulfilled desire to conceive of any duration or attendance for infertility investigations or treatment, and a prescribed period of attempt at weight loss. A BMI $\geq$ 25 kg/m^2 was used to define overweight, and $\geq$ 30 kg/m^2 to define obesity (World Health Organization, 2016); participants were required to be at least overweight. Morbid obesity was defined by BMI $\geq$ 40 kg/m^2. Studies were excluded if participants were not actively attempting pregnancy, or had an illness or eating disorder that might result in weight fluctuation.

Types of interventions

Any intervention for weight loss allowed inclusion, for example prompt for weight reduction, dietary modification, exercise, psychological or behavioural counselling, or the drug orlistat. Bariatric surgery was not included. Alternative or control interventions were included where evaluated in included studies.

Types of outcome measures

162 Primary outcomes were weight change, achievement of pregnancy, and live birth, the latter

163 defined as the complete expulsion or extraction from its mother of a product of fertilisation,

164 which, after such separation, breathes or shows any other evidence of life such as heart beat,

165 umbilical cord pulsation, or definite movement of voluntary muscles, irrespective of whether

166 the umbilical cord has been cut or the placenta is attached (National Institute for Health and

167 Clinical Excellence, 2013).

168

169 Secondary outcomes were BMI change; waist circumference change (North American

170 Association for the Study of Obesity *et al.*, 2000); miscarriage, defined as a loss of pregnancy

171 before 23+6 weeks of gestation (Anonymous , 2012); ovulation improvement, with anovulation

172 defined by suboptimal rise in LH, or a below-threshold serum progesterone level taken in the

173 mid-luteal phase of the menstrual cycle (National Institute for Health and Clinical Excellence,

174 2013); improvement in menstrual regularity, with irregular cycles defined as outside the range

175 of 26-36 days (National Institute for Health and Clinical Excellence, 2013); and time to

176 conception.

177

178 ***Search methods for identification of studies***

179

180 The dates searched were 1 January 1966 to 19 March 2016. No restriction was placed on

181 language of origin, ~~or publication status~~and studies could be included regardless of whether

182 they had been published **(AUTHOR: please would you clarify what you mean by 'status' here?)**.

183 The electronic databases used were MEDLINE, EMBASE and the Cochrane Library. Additional

184 studies were identified through review of the references of the retrieved papers, contact with

185 study authors, and online searching of Google and Google Scholar (Google Inc., Mountain View,

186 CA, USA). The search strategy used for MEDLINE and EMBASE is given in the Supplementary

187 Data **(AUTHOR: we tend not to include Appendices, therefore these data have been divided and

188 renamed as supplementary files.)**.

> **Commented [BDA4]:** Reworded "publication status for clarity"
>
> **Formatted:** Font: Bold
>
> **Commented [BDA5]:** Thank you

8

189

Data collection and analysis

190

191

Selection of studies

192

The titles and abstracts obtained were screened by one author (DB). To verify the process of

193

selection, the titles and abstracts for the year 2000 were independently screened by DB and AA,

194

with full agreement with respect to papers to be included or excluded. Thus full text versions of

195

all relevant papers were retrieved by DB for further scrutiny by both reviewers. Any

196

disagreement between the two as to which studies to include was resolved by discussion.

197

198

Data collection process

199

Data were extracted by one reviewer (DB), and checked by a second (AA). Discrepancies were

200

resolved by discussion between the reviewers, and a third reviewer (SB) was available for

201

referral as necessary. Study authors were contacted as required for missing data or clarification.

202

203

For each included study, the information collected included study design; methods; location,

204

setting and time period; information about the participants (demographics, infertility diagnosis,

205

BMI, eligibility criteria); drop-outs; the types of interventions assessed and their descriptions;

206

and outcomes, including pregnancy, live births, weight or BMI change, miscarriage, ovulation

207

and menstrual change. For men, semen analysis parameters were captured. **(AUTHOR: please**

208

would you re-state those outcomes here, for clarity? Thank you.). Any data on barriers to weight

209

loss were also captured. Data on costs and cost-effectiveness were sought but not found.

210

211

Assessment of risk of bias in individual studies

212

RCTs were assessed for their methodological quality using the Cochrane Risk of Bias Tool

213

(Higgins *et al.*, 2011).

214

215

Formatted: Font: Bold

Commented [BDA6]: Done

216 Non-randomised studies were assessed using a checklist developed for the Review Body for

217 Interventional Procedures (ReBIP) (64)(AUTHOR: please would you use the correct format of

218 citation?). The ReBIP is an independent review body that carries out systematic reviews for the

219 National Institute for Health and Care Excellence's Interventional Procedures Programme. The

220 checklist was adapted from several sources (Verhagen *et al.*, 1998; Khan *et al.*, 2001; Downs

221 and Black, 1998), and has been used in many systematic reviews. It includes assessment of

222 sample selection; clarity of inclusion and exclusion criteria; baseline comparability of

223 participants; consecutive selection of patients; prospective data collection; clarity of

224 intervention descriptions; experience of person administering the intervention;

225 appropriateness of staff, place and facilities where participants were treated; consideration of

226 important incomes on clinical effectiveness, cost-effectiveness, or learning curves; use of

227 objective outcome measures; blinding of outcome assessment; adequacy of duration of follow-

228 up to detect important effects on outcomes of interest; information provision on dropouts, and

229 their similarity to completers; identification of important prognostic factors; and adjustment of

230 analyses for confounding factors.

231

232 *Summary measures*

233 Results were summarised descriptively. In the outcome summary tables, numbered rankings

234 are provided in an effort to demonstrate which study interventions reported more favourable

235 outcomes, with a lower number indicating a better outcome. Meta-analysis was undertaken

236 where possible. Risk ratios (RR) and mean differences with 95% CI between groups are

237 reported.

238

239 *Synthesis of results*

240 Data were imported into Review Manager Version 5.3.5 (The Cochrane Collaboration, Oxford,

241 UK) for quantitative synthesis. A random effects, rather than a fixed effect model, was used for

Formatted: Font: Bold

Commented [BDA7]: Citation not required. Sources mentioned below

242 meta-analysis, owing to unavoidable population and intervention heterogeneity, as anticipated

243 in interventions for weight loss.

244

245 *Assessment of heterogeneity*

246 Statistical heterogeneity was investigated by visual inspection of forest plots, the Q-test (with

247 p<0.1 implying statistical heterogeneity) and by examining the I^2 statistic (Higgins and

248 Thompson, 2002), where a result >50% was taken to indicate substantial statistical

249 heterogeneity.

250

251 *Sensitivity analyses*

252 Sensitivity analysis was planned to compare randomised trials judged to be at low risk of bias

253 for allocation concealment or randomisation with those judged to be at higher risk of bias;

254 however, the small numbers of trials precluded this.

Results

Outcome of the search

Details of the selection process for studies is summarised in the PRISMA flow diagram (Figure 1) (**AUTHOR**: the quality of this figure still seems poor. If possible, please can you send to me a higher quality file?). Seventeen study authors were contacted for clarification or further information; ten provided helpful further information.

Full details of all the studies and interventions are provided in Supplementary Table SI. There were 14 RCTs, six non-randomised studies with comparison groups (NRCTs), and twenty cohort studies with interventions. Ten studies took place in Australia, seven in the USA, three each in Italy and the Netherlands, and two in Denmark. One each came from Belgium, Brazil, Canada, Egypt, France, Germany, India, Iran, Jordan, Pakistan, Russia, Saudi Arabia, Slovakia, Turkey and the UK. Three studies were multi-centre.

Enrolment varied from eight participants (Faure *et al.*, 2014) to 577 (Mutsaerts *et al.*, 2016). Attrition rates ranged from 10.6% (Mutsaerts *et al.*, 2016) to 66.7% (Turner-McGrievy *et al.*, 2014).

Description of populations

Mean age of study groups varied from 25 years (Lazurova *et al.*, 2004) to 35.4 years (Chavarro *et al.*, 2012). Ethnicity was reported in six papers, with between 55% (Turner-McGrievy *et al.*, 2014) and 87.5% white (Mutsaerts *et al.*, 2016).

281   Duration of infertility, where reported, ranged from a mean of 19.5 months (Palomba *et al.*,

282   2008) to 11 years (Aliyeva *et al.*, 1993). Some studies addressed women with any infertility

283   history. Others centred on women undergoing fertility treatments or planning to start

284   immediately following the intervention. Some were exclusively catered to persons with

285   polycystic ovary syndrome (PCOS), with the syndrome defined by Rotterdam 2004 consensus

286   criteria (ESHRE and Group, ASRM-Sponsored PCOS Consensus Workshop, 2004) in ten cases,

287   National Institutes of Health (NIH) criteria (Zawadzki and Dunaif, 1992) in one case, ultrasound

288   appearance of the ovaries in two cases, and not specified in five cases. One study used PCOS as

289   an exclusion criterion (Moran *et al.*, 2003).

290

291   In eight studies, patients were anovulatory, and in seven studies patients had irregular

292   menstrual cycles. Three papers were centred on patients who were resistant to clomiphene

293   citrate for ovulation induction.

294

295   The lowest mean BMI was 24.5 kg/m^2 (Chavarro *et al.*, 2012), and the highest was 44 kg/m^2

296   (Mahoney, 2014; Hakonsen *et al.*, 2011).

297

298   Two studies were centred on men. One had participants with sperm DNA fragmentation who

299   were overweight or obese (Faure *et al.*, 2014), while the other examined obese men only

300   (Hakonsen *et al.*, 2011). One study examined a weight loss intervention in couples (Homan *et*

301   *al.*, 2012).

302

303   ***Description of interventions***

304

305   Table 1 provides brief details of the types of interventions tested. In general, interventions were

306   poorly described, with insufficient detail to allow their replication. Where described, most

307   reducing diets followed healthy eating principles by reducing fat and refined carbohydrate

308   intake. Where available, studies described calorie intakes ranging from 1000 to 2000kcal/d

309   (depending on body size), apart from three studies that tested very low calorie diets as part of

310   their reducing diets (Tsagereli 2006, Kiddy 1992, van Dam 2004) and one that tested a very low

311   carbohydrate ketogenic diet (Mavroupolos 2005). If physical activity advice or programmes

312   were incorporated into interventions, they were generally for aerobic exercise. There was no

313   clear evidence that any particular regime was more effective for weight loss, providing there

314   was a weight reduction diet prescribed.

315

316   Five of the 16 interventions incorporating both a dietary and physical activity component

317   provided some part of the intervention in a group setting. Only two interventions were

318   described involving couples. One study (Chavarro *et al.*, 2012) tracked participants' weights

319   after administering a lifestyle questionnaire. While this is not strictly a weight-loss intervention,

320   we have included it with the other cohort studies, because there is evidence that weight loss

321   occurs with enrolment in studies tracking weight, even with minimal intervention (Waters *et al.*,

322   2012; Johns *et al.*, 2016).

323

324

325   ***Quality of studies***

326

327   The quality of the studies included was variable. For full details of risk of bias assessment for all

328   the randomised studies please see Supplementary Table SII. The quality of the studies included

329   was variable. Three of fourteen RCTs had four or five out of seven domains with low risk of bias,

330   e.g. allocation concealment, incomplete outcome data, but the Lifestyle trial (Mutsaerts *et al.*,

331   2016) stood out as the one with best quality. All studies were of high risk of bias with respect to

332   blinding of participants to treatment allocation, and all had low risk of bias in at least two

333   domains. Five of 26 non-randomised studies, having eight to nine of 14 domains with low risk of

14

334 bias, were judged to be good quality. Full details of the risk of bias assessment for the non-

335 randomised studies are given in Supplementary Table SIII.

336

337 ***Studies involving female infertility participants***

338

339 *Pregnancy*

340 Aggregated data from six RCTs show that women who received a combination of a reducing diet

341 and exercise had higher pregnancy rates than those who underwent standard care**(AUTHOR: is**

342 **there a word missing? Please would you recheck the sense here? Thank you.)**, 238/434 (54.8%)

343 versus 221/443 (49.9%); RR 1.59, 95% CI (1.01, 2.50) (Figure 2). The trial by Mutsaerts *et al*

344 (2016)) contributed significantly to the heterogeneity, I^2=71% and its exclusion in a post-hoc

345 sensitivity analysis reduced I^2 to 0%. Although the numbers of participants in other RCTs were

346 too few for any meaningful conclusions to be drawn, a very small trial was unable to

347 demonstrate any advantage of diet alone, while another suggested that orlistat might be

348 beneficial. The results of an NRCT (Clark et al, 1998) support the result of the meta-analysis

349 favouring diet and exercise. The study by Koning et al (2015) did not show any advantage

350 associated with motivational interviewing.

Formatted: Font: Bold

Commented [BDA9]: Added the word 'care'

351 Table 2 details the reproductive outcomes for all included studies. Diet and exercise studies

352 without control populations achieved rates that were comparable to those included in the meta-

353 analysis.

354

355 *Live births*

356 Data from five RCTs (Figure 3) did not favour diet and exercise over standard care in terms of

357 live birth rates which were 48.9% (195/399) versus 46.8% (190/406) respectively; RR 1.54,

358 95% CI (0.93, 2.56). Mutsaerts et al (Mutsaerts *et al.*, 2016) again contributed significantly to

359 the heterogeneity, I^2=69%. Its exclusion in a post-hoc sensitivity analysis reduced I^2 to 0%, and

360 resulted in diet and exercise having a statistical advantage, RR 1.86, 95% CI (1.25, 2.77). The

361 NRCT (Clark *et al.*, 1995; Clark *et al.*, 1998) also favoured the intervention arm, 45/67 (67.2%)

362 versus no treatment (0/20); RR 28.10, 95% CI (1.81, 436.85). Motivational interviewing was

363 also not associated with an increased live birth rate.

364

365 Table 2 details live birth rates for all included studies. Women in studies on diet and exercise

366 without control groups had lower success rates than those included in the meta-analysis.

367 Khaskheli et al (Khaskheli *et al.*, 2013), who did not provide details of their intervention,

368 reported a 37.6% (32/85) livebirth rate, while Crosignani et al, (Crosignani *et al.*, 2003), who

369 administered a 1200 kcal/day diet along with aerobic exercise, achieved a 24.2% (8/33) rate.

370 The numbers of participants in the other studies included in Table 2 were too few for any

371 meaningful conclusions to be drawn.

Spontaneous and IVF conceptions

Pooled data from RCTs (Figures 4 and 5) show that, reducing diets and exercise were not associated with a higher chance of spontaneous conception [28.3% (86/304) versus 15.9% (50/315); RR 2.20, 95% CI (0.98, 4.93)].

Miscarriages

A combination of a reducing diet and exercise was associated with a pooled miscarriage rate of 13.4 per hundred women (48/357) or 23.3% of pregnancies (48/206) (Figures 6 and 7). The control arm had a pooled miscarriage rate of 8.7 per hundred women (31/355) or 15.6% of pregnancies (31/199). This shows no benefit of diet and exercise [combined RR 0.96, 95% CI (0.89, 1.04) per woman and RR 0.91, 95% CI (0.91, 0.82, 1.01) per pregnancy]. Miscarriage rates in the other studies on diet and exercise vary widely (Table 2).

Ovulation

One RCT (Palomba *et al.*, 2010) found a 37.5% (12/32) ovulation improvement with a combination of reducing diet and exercise, while its control group had a 9.3% (3/32) improvement rate; RR 4.00 95% CI (1.25, 12.84) (Figure 8). An NRCT, also using diet and exercise, that had the highest rate of improvement of all included studies in its intervention group [**AUTHOR: again, does this sentence read correctly? Please would you recheck?**], 89.6% (60/67), while none of the participants in the control group saw improvement; RR 37.37, 95% CI (2.41, 578.65).

One RCT (Kumar and Arora, 2014) compared the use of 120mg of orlistat twice daily and a lifestyle modification programme with use of the lifestyle programme alone. The orlistat group had a 50% (15/30) rate of ovulation, while the control group had a 6.7% (2/30) rate; RR 7.50, 95% CI (1.88, 29.99).

17

399 One RCT (Legro *et al.*, 2015) compared the proportions of total clomiphene treatment cycles

400 that were ovulatory in each group. The group whose treatment was preceded by diet and

401 exercise advice and the oral conceptive pill (OCP) had the best ovulation rate, 67.1% (94/140),

402 while the lifestyle alone group and control (OCP alone) group had rates of 60.3% (82/136) and

403 46.1% (71/154) respectively.

404

405 Another RCT (Thomson *et al.*, 2008) randomised its participants, who had PCOS, to receive an

406 energy-restricted high-protein diet alone (DO), combined with aerobic exercise (DA), or

407 combined with both aerobic and resistance exercise (DC). DO saw a 50% (6/12) improvement

408 in ovulation, DA a 50% (3/6) improvement, and DC a 42.8% (3/7) improvement.

409

410 Table 2 shows the ovulation rates in cohort studies of diet without controls. One study using a

411 very low calorie diet (van Dam *et al.*, 2004) had a relatively good ovulation improvement rate,

412 60% (9/15). Other studies had comparatively low rates, including one using a hypocaloric 1434

413 kcal/day diet (Thomson *et al.*, 2009) which achieved a 19.2% (10/52) rate, and another

414 (Turner-McGrievy *et al.*, 2014) which saw no improvement using either an low-calorie diet

415 (LCD) (**AUTHO**R: please define LCD) or a vegan diet. One study compared a hypocaloric high

416 protein diet to structured exercise training (SET) (Palomba *et al.*, 2008), and achieved a 25%

417 (5/20) improvement rate with diet, and a 65% (13/20) improvement with exercise.

418

419 A study comparing ovulation improvement in women receiving acupuncture to those receiving

420 an unspecified diet (Aliyeva *et al.*, 1993) had a 55% (11/20) improvement with the former, and

421 46.7% (28/60) improvement in the latter; RR 1.18, 95% CI (0.73, 1.90).

422

423 *Menstrual irregularity*

424 In clomiphene citrate resistant PCOS women, a single trial (Palomba *et al.*, 2010), showed that

425 hypocaloric diet and exercise was significantly more likely to result in menstrual improvement,

Commented [BDA11]: Placed full nomenclature "low calorie diet" ahead of the abbreviation LCD

Formatted: Font: Bold

426   than observation only: 34.4% (11/32) versus 9.3% (3/32); RR 3.67, 95% CI (1.13, 11.92)

427   (Figure 9). Other studies without control groups also suggest that diet and exercise were

428   associated with improvement in menstrual regularity (Table 2). There were no RCTs evaluating

429   the role of dietary interventions alone or motivational interviewing in regulating menstrual

430   cyclicity. Data from observational and often uncontrolled studies of other interventions show

431   variable levels of success (Table 2).

432

433   *Oocyte retrieval*

434   Data from a single RCT (Figure 10) suggest that a low glycaemic index diet (Becker *et al.*, 2015)

435   could improve oocyte yield in IVF. The mean (SD) number of oocytes in women in the

436   intervention arm was 7.75 (5.39), compared to 4.18 (SD 3.01) in controls; mean difference -

437   3.57, 95% CI (-6.87, -0.27).

438

439   *Time to conception*

440   The Lifestyle trial (Mutsaerts *et al.*, 2016) reported that the median time to conception (TTC)

441   resulting in a term live birth was 7.2 months (interquartile range (IQR) 2.6, 12.0) in the

442   intervention group, who underwent a multidisciplinary programme based on diet and exercise,

443   versus 5.2 (IQR 2.4, 10.1) in the control group, who were allowed fertility treatment from the

444   start (P=0.06). An RCT comparing energy-restricted low protein and high protein diet groups

445   who both received exercise instruction (Moran *et al.*, 2003) reported a 4-5 week TTC regardless

446   of group. A cohort study which advised women to lose 10% of their body weight (Kort *et al.*,

447   2013; Kort *et al.*, 2014) found that those who met the target had a mean TTC of 227 days, while

448   those who had not had a mean of 231 days.

449

450   *Weight loss*

451   Aggregated data from RCTs suggest that a combination of a reducing diet and exercise resulted

452   in greater weight loss than that achieved in control groups (Figure 11); mean difference -3.98 kg

453   (95% CI -4.85, -3.12). Diet alone was also shown to be more effective in a small RCT; mean

454   difference -5.23kg (95% CI -7.42, -3.04) (Becker *et al.*, 2015).

455

456   In non-randomised trials, Clark et al (Clark *et al.*, 1998) reported significantly greater weight

457   loss from diet and exercise; mean difference -9.00kg (95% CI -10.88, -7.12). Two non-

458   randomised trials testing motivational interviewing also found greater weight loss; mean

459   difference -3.21kg (95% CI -5.93, -0.49kg). Changes in weight, BMI and waist circumference for

460   other studies are provided in Table 3. Generally results are not inconsistent with studies with

461   either randomised or non-randomised control groups.

462

463   ***Comparisons with metformin***

464

465   *Pregnancy*

466   Three small RCTs evaluated lifestyle interventions versus metformin (Figure 12). None was able

467   to show any superiority of metformin over the alternative intervention, but it is difficult to be

468   confident about these outcomes owing to the small sample sizes involved.

469

470   *Ovulation*

471   Two small RCT of diet or drug treatment (Figure 13) were unable to show any benefit over

472   metformin. Details of other studies are in Table 2.

473

474   *Menstrual irregularity*

475   Metformin did not appear to improve menstrual regularity in a number of small trials

476   comparing it to diet and exercise with or without drug treatment, diet alone or acarbose (Figure

477   14). Details of other studies are in Table 2.

478

479   *Weight loss*

480 Weight, BMI and waist circumference changes for studies comparing metformin with lifestyle

481 interventions are provided in Table 3.

482 **AUTHOR:** please would you mention Supplementary Table SIII (Quality assessment for non-

483 randomised studies) at the appropriate place in the Results section? (Please renumber the

484 Supplementary Tables if order in text requires it.) Thank you.

485 *Summary of the key findings in infertile women*

486

487 In overweight and obese infertile women, weight loss is associated with improved chances of

488 becoming pregnant, and possibly spontaneous conception pre-IVF. Ovulation and menstrual

489 irregularity are also aided. There appears to be no significant difference between weight loss

490 interventions and controls with respect to rates of miscarriage and IVF conceptions. The few

491 studies that included metformin showed no significant difference between weight loss

492 interventions and the drug for achieving pregnancy or improvement in ovulation status;

493 similarly there was no difference between the two groups in menstrual improvement.

494

495 *Barriers to weight loss in infertile women*

496

497 Very little has been reported regarding the perceived barriers to weight loss in overweight and

498 obese infertile women. Two of the included studies attempted in some way to evaluate these.

499 In the trial by Thomson et al (Thomson *et al.*, 2008), 104 participants were allocated to receive

500 an energy restricted diet only (DO), the same diet combined with five sessions of aerobic

501 walking and jogging exercise per week (DA), or the diet combined with aerobic and resistance

502 training exercises (DC), where resistance exercise replaced two of the aerobic sessions (110)

503 (**AUTHOR:** please would you use the correct format for the citation? Thank you.). Forty-three of

504 the participants in the trial (DO=13, DA=11 and DC=19) completed a validated Exercise

505 Benefits/Barriers Scale at weeks 0, 10 and 20 (Thomson *et al.*, 2016). This was to determine

506 their perceptions of the benefits and barriers to participation in exercise. The scale included 43

Formatted: Font: Bold

Formatted: Font: Not Bold

Formatted: Font: Not Bold

Commented [BDA12]: Lines 328-330

Commented [BDA13]: Second citation removed as wasn't required.

Formatted: Font: Bold

items with statements related to ideas about exercise and a four-point Likert scale, with 4 = strongly agree, 3 = agree, 2 = disagree and 1 = strongly disagree. At baseline, the statements with the highest agreement were: "exercise tires me" [mean (SD), 2.86 (0.71)]; "exercise is hard work for me [2.79 (0.67)], and "I am fatigued by exercise" [2.60 (0.62)]. Those with the lowest agreement were: "my family members do not encourage me to exercise" [1.56 (0.59)], "my spouse does not encourage exercising" [1.63 (0.70)], and "I think people in exercise clothes look funny" [1.72 (0.59)].

Barrier scores were reduced by week 10 in this study, regardless of treatment allocation, with no further reduction by week 20 (P≤0. 001). Time expenditure and physical exertion as perceived barriers saw a significant reduction (P≤0.003), while family discouragement saw no change (P=0.6).

Participants in the study by Galletly et al (Galletly *et al.*, 1996), in addition to completing a 24-week programme with weekly meetings comprising 1 hour of exercise and 1 hour of dietary and psychiatric counselling, completed the Rosenberg Self-Esteem Scale and the General Hospital Anxiety and Depression Scale at the start and end of the study. At baseline, those who dropped out before the end of intervention exhibited higher anxiety (p<0.02) and depression scores (p<0.069), and lower self-esteem scores (p<0.056) than those who completed. Completion was associated with a significant improvement in self-esteem (p<0.0001) and depression (p<0.006), and a non-significant reduction in anxiety scores.

Based on what little evidence is available, overweight infertile women appear most deterred from exercise by the perception that it causes fatigue and is hard work. These perceptions, as well as depression, seem to decrease with continuation of an exercise programme. Very few women seem to be discouraged from exercise by family members. Those women who discontinue exercise would appear to be more anxious and/or depressed at the outset.

534

Studies involving male infertility participants

536

Achievement of pregnancy, live birth rate, and Improvement in sperm DNA integrity

One cohort study (Faure *et al.*, 2014) administered a nutritionist-led personalised dietary

programme of an unreported nature coupled with exercise, aimed at reducing intra-abdominal

fat over a 3-8 month period, to eight men who had significant abdominal fat and at least 25%

sperm DNA fragmentation and unexplained infertility (Table 4). The partners of all eight

achieved pregnancy, three naturally and five through IUI, and all went on to have live births. Six

who allowed their semen samples to be analysed both before and after the intervention all had

an improvement in the degree of sperm DNA fragmentation.

545

AUTHOR: could the following sections be edited to avoid repeating most of the data that are
shown in Table 4, as we try to minimise such repetition in the results section? Thank you,

Improvement in semen analysis parameters

A cohort of 44 men with BMI 33-61 kg/m^2 underwent a programme based on a healthy diet and

daily exercise (Hakonsen *et al.*, 2011). Semen analyses before and afterward were compared in

27 men, and the results were as shown in Table 4.

552

The group with 3.5-12.1% weight loss (Group 1, n=9) saw a mean change in sperm

concentration of -11 million/ml (95% CI -49, +27). The group with 12.2-17.1% (Group 2, n=9)

loss had a mean change of +19 million/ml (95% CI -23, 61). The group with 17.2-25.4% loss

(Group 3, n=9) had a mean change of +17million/ml (95% CI -24, 58).

557

Group 1 saw a mean change in progressive sperm motility of -2%, 95% CI (-15,11). Group 2 had

a mean change +4%, 95% CI (-10, 18). Group 3 had a mean change +11%, 95% CI (-3, 25).

560

23

561 Group 1 saw a mean change in normal sperm morphology of 0%, 95% CI (-2, 4). Group 2 had a

562 mean change of +1%, 95% CI (-3, 4). Group 3 had s mean change of +4%, 95% CI (1,7).

563

564 *Change in weight*

565 The cohort study by Hakonsen et al. (Hakonsen *et al.*, 2011) achieved median weight change -

566 22kg, range -4 to -39 kg. The cohort study by Faure et al. (Faure *et al.*, 2014) achieved a mean

567 weight reduction of -4.40 (SD 5.0 kg).Table 4 also summarises the weight loss achieved in both

568 studies.

569

570 *Summary*

571 The relative paucity of studies in overweight and obese men seeking fertility has made it

572 difficult to draw firm conclusions regarding the benefits of weight loss. However, improvements

573 in sperm concentrations, motility and normal morphology have been suggested, though these

574 have not been statistically significant. Improvement in sperm DNA integrity has also been

575 suggested, and this might be linked to an improved live birth rate.

576

Discussion

Key findings

The present systematic review and meta-analysis found that the weight loss interventions, particularly diet and exercise, improved pregnancy rates and ovulatory status. A trend toward more natural pregnancies, but not IVF pregnancies, occurred. Miscarriage rates were unaffected by weight loss interventions and, as reports of higher oocyte yield and improved menstrual regularity are based on single trials, further research is needed before firm conclusions can be made. A lack of RCTs in men and couples, and of studies evaluating barriers to undertaking weight loss in overweight and obese infertile populations, is evident. The quality of the studies we included was variable, but the one with the lowest risk of bias was the Lifestyle trial (Mutsaerts *et al.*, 2016), whose intervention also ranked highly for both pregnancy and live birth rates.

Women

Pregnancies and live births

Weight loss interventions, particularly those with reducing diets and exercise, were more likely than controls to result in pregnancy. Live births were reported by ~~only a few~~relatively fewer~~r~~ studies. **(AUTHOR: correct?)**, usually involving women undergoing fertility treatments such as OI or IVF. Data from studies predating the Lifestyle trial in 2016 (Mutsaerts *et al.*, 2016) suggested that diet and exercise combinations were superior to standard care, but inclusion of this trial changed this. Those in the intervention arm underwent a 6-month programme based on diet and exercise, prior to undergoing 18 months of fertility treatments. Those in the control arm commenced fertility treatments immediately. The primary outcome was vaginal birth of a healthy singleton of at least 37 weeks' gestation within 24 months after randomisation. The trial

Commented [BDA14]: Reworded.

Formatted: Font: Bold

604   was well conducted, with low risk of bias. This was the largest study in the review, and it carried

605   substantial weight during meta-analysis. The results deviated from the trend exhibited by the

606   preceding trials, resulting in marked increase in heterogeneity. It is possible that the results

607   might have been different if the control group underwent 6 months of no intervention

608   observation prior to 18 months of treatment. The trial found that significantly more women in

609   the intervention group had ongoing pregnancies from natural **(AUTHOR: the term natural' is

610   usually preferred throughout but I leave the final decision to you.)** conception than the control

611   group, consistent with our other findings.

612

613   Studies reporting the highest pregnancy and live birth rates were not necessarily those with

614   highest weight loss. Clark et al, had a high live birth rate of 67.2% in the diet and exercise arm of

615   their NRCT, while also achieving one of the highest weight changes, mean -10.2kg (SD 4.3)

616   (Clark *et al.*, 1995; Clark *et al.*, 1998). On the other hand, the intervention arm of the Mutsaerts

617   et al (2016) RCT reported a live birth rate of 53.2%, but only achieved a mean weight change of

618   -4.4 kg (SD 5.8).

619

620   *Miscarriages*

621   Studies with some of the lowest rates of weight loss reported fewer miscarriages in their

622   intervention arms, but the data are insufficient to draw conclusions (Tables 2 and 3).

623

624   *Ovulation*

625   Weight loss interventions, regardless of their nature, were significantly more likely than control

626   interventions to achieve ovulation in anovulatory women. Improvements were not necessarily

627   greatest in those studies achieving the greatest weight loss.

Formatted: Font: Bold

Commented [BDA15]: I'll accept your suggestion

628

629 *Menstrual irregularity*

630 A single RCT suggested that diet and exercise were significantly more likely to improve

631 menstrual cycles than a control intervention (Palomba *et al.*, 2010). High rates of menstrual

632 improvement were seen in studies with good weight or BMI reduction. Qublan et al (2007), for

633 example, with a 1200-1400 kcal diet in their RCT, had a 61.9% menstrual improvement and

634 achieved one of the better BMI reductions, with a mean change of -4.8 kg/m^2.

635

636 *Spontaneous and IVF conceptions*

637 Studies included women expected to proceed to in-vitro treatments after a period of weight

638 loss. Many women were able to conceive without further assistance through weight loss alone.

639 All interventions showed an improved rate of spontaneous conception in comparison to a

640 control. There was however no significant difference between interventions and controls when

641 it came to IVF conceptions. Similar spontaneous conception rates were seen regardless of type

642 of intervention and/or amount of weight lost.

643

644 *Change in weight, BMI and waist circumference*

645 No class of intervention was consistently better in achieving reduction in weight compared to

646 others. Trials with longer interventions and follow-up sometimes suffered from higher rates of

647 study drop-out, for example 20.4% in the 12-month Sim et al RCT (Sim *et al.*, 2014a) and 10.6%

648 in the 6-month Mutsaerts et al RCT (Mutsaerts *et al.*, 2016), both of which mainly had diet and

649 exercise. Others had no dropout: Karlsen et al after 7-8 months (Karlsen *et al.*, 2013) and

650 Koning et al after 6 months (Koning, 2015), and both included motivational interviewing. This

651 suggests that enhancing motivation plays a key role in compliance. Programmes with strict

652 dietary and exercise modifications may be more likely to see discontinuation. The study with

653 the most weight lost, the cohort study by Mavropoulos et al (Mavropoulos *et al.*, 2005), utilised

654   a very restrictive diet for 6 months, and had very low recruitment (n=11) and a high rate of

655   drop-out (58.5%).

656

657   *Metformin*

658   The meta-analyses showed that weight loss interventions have a non-significant advantage over

659   metformin with respect to achievement of pregnancy or improvement of ovulation status. There

660   was also no significant difference in menstrual regularity improvement. In light of these

661   findings, and the gastro-intestinal side-effects common with metformin (Kumar and Arora,

662   2014; Qublan *et al.*, 2007), lifestyle interventions should remain the first line therapy for

663   improvement in ovulation and menstruation.

664

665   **Interventions in infertile men**

666

667   There was very little evidence available to judge the effectiveness of weight reduction strategies

668   in men, and this is an area ripe for future research. The two studies both utilised a diet and

669   exercise combination, with neither providing adequate details of the intervention.

670

671   **Types of diet**

672

673   As expected, the dietary interventions used were based on caloric restriction, and were usually

674   consistent with weight reduction advice from national guidelines (National Clinical Guideline

675   Centre, 2014; Dietz *et al.*, 2015). It is hard to say, based on the data obtained, whether any

676   particular degree of restriction was superior for achievement of weight loss, particularly given

677   the frequent pairing of diet with exercise. Some of the RCTs used individualized diets, tailoring

678   caloric deficit to baseline weight (Becker *et al.*, 2015; Duval *et al.*, 2015b). Others mentioned a

679   hypocaloric range within which dietary intakes would fall (Kumar and Arora, 2014; Qublan *et*

680   *al.*, 2007; Thomson *et al.*, 2008; Turner-McGrievy *et al.*, 2014), generally between 1200 and

681   1800 kcal/day. Dieticians were used to assist with dietary advice in a few cases (Duval *et al.*,

682   2015b; Turner-McGrievy *et al.*, 2014; Thomson *et al.*, 2008; Mutsaerts *et al.*, 2016). The RCT

683   with the lowest recruitment and highest discontinuation rate used a vegan diet in one of its

684   study arms (Turner-McGrievy *et al.*, 2014), suggesting poor acceptance.

685

686   *Types of exercise*

687

688   The majority of exercise interventions sought to increase weekly aerobic activity in participants

689   in order to increase caloric expenditure. The most frequent feature seen in the RCTs was an

690   increase in the number of steps or amount of walking by participants (Duval *et al.*, 2015b;

691   Karimzadeh and Javedani, 2010; Legro *et al.*, 2015; Mutsaerts *et al.*, 2016; Sim *et al.*, 2014a;

692   Thomson *et al.*, 2008). Fewer RCTs (**AUTHOR: correct, or studies?**) included strength or

693   resistance training (Karimzadeh and Javedani, 2010; Moran *et al.*, 2011b; Thomson *et al.*, 2008),

694   and this was always in addition to the basic aerobic approach. Thomson et al found that

695   addition of resistance training did not result in a significantly different weight loss in their RCT

696   of diet alone, diet with aerobic exercise, or diet with aerobic and resistance exercise (Thomson

697   *et al.*, 2008). Physical activity interventions were in some cases individualised (Duval *et al.*,

698   2015a; Moran *et al.*, 2011a) and in others in the form of group sessions (Moran *et al.*, 2003),

699   with occasional use of a kinesiologist (Duval *et al.*, 2015a) or physiotherapist (Kumar and

700   Arora, 2014).

701

702   *Types of weight loss medication*

703

704   The use of weight loss drugs is contraindicated during pregnancy (Department of Veterans

705   Affairs, 2014), and the studies using them aimed to reduce weight prior to attempting

706   pregnancy. One trial (Legro *et al.*, 2015) recommended barrier contraception during its

707   intervention. Oral medications used in the studies included orlistat, a lipase inhibitor;

Commented [BDA16]: Correct.

Formatted: Font: Bold

708 sibutramine, a selective serotonin and norepinephrine reuptake inhibitor; and acarbose, an

709 alpha-glucosidase inhibitor shown to induce modest weight loss, though not suitable for weight

710 maintenance (Hauner *et al.*, 2001). Of these, sibutramine, which has been withdrawn in Europe

711 and the USA but is still available on the internet, has been shown in a large study to have a risk

712 of cardiovascular defects in unborn infants (Källén, 2014), while the same study showed no risk

713 of birth defects from orlistat use. The safety of acarbose in pregnancy is not established. Orlistat

714 was shown to be superior to a control with respect to achievement of pregnancy and ovulation

715 in a single study (Kumar and Arora, 2014). Until further evidence is available, lifestyle

716 interventions should still be considered thefirst line therapy, with drug use reserved for

717 monitored trials.

718

719 ***Strengths and limitations of the review***

720

721 This review has added to the scope of the systematic review by Sim et al (2014b) by going

722 beyond examining overweight and obese women undergoing fertility treatment to encompass

723 individuals of both genders, and couples, from a variety of infertility circumstances undergoing

724 non-surgical weight loss programmes. A wide search strategy meant that we were thus able to

725 capture 40 studies, in comparison to the 11 in that review (Sim *et al.*, 2014b). Author contact,

726 initiated with 17 study authors, was another strength, as this allowed unreported information

727 to be gained, and clarification of unclear information. Nevertheless, we cannot exclude

728 publication bias, where studies with less positive outcomes remain unreported.

729

730 ***Clinical recommendations***

731

732 Overweight and obese persons seeking fertility should be educated on the effects of being

733 overweight or obese on the ability to achieve pregnancy, and the benefits of weight reduction,

734 including improvement in pregnancy rates, and a reduced need for OI and IVF.

30

735

736 A combination of a reduced calorie diet, which is not overly restrictive, and aerobic exercise,

737 intensified gradually, should form the basis of programmes designed for such individuals. As

738 compliance is key to success, coached sessions of achievable frequency, e.g. weekly, for up to 6

739 months, should be considered. Motivational interviewing techniques might also be useful. An

740 advantage of fertility care is that couples are catered to, and dual enrolment may result in better

741 adherence, as partners tend to motivate each other.

742

743 *Research recommendations*

744

745 Future research would ideally be in the form of large multi-centre RCTs including both women

746 and men, ideally couples, attending fertility clinics and having at least one partner with a BMI

747 within the overweight or obese range. Based on the data from RCTs of diet and exercise

748 examined here, we estimate that a trial would require over 454 participants to detect a

749 difference of 15% in pregnancy rates (90% power, p < 0.05, control pregnancy rate 50%,

750 intervention rate 65%). This figure does not take account of losses to follow-up, and would need

751 to be considerably inflated, depending on drop-out rates in feasibility and pilot work.

752

753 A reasonable control intervention would be the administration of dietary and exercise advice

754 only, to be undertaken for a brief period only (**AUTHOR: correct?**), to reduce persons allocated

755 to this arm feeling as though their fertility treatments were being delayed with no intervention.

756 Similar durations employed between intervention and control groups prior to starting fertility

757 treatments would allow for fair comparisons with respect to weight loss and reproductive

758 outcomes.

759

760 A long duration of follow-up, spanning decades, might answer further questions, including

761 whether obstetric problems related to weight such as gestational diabetes or caesarean rates

Commented [BDA17]: Rearranged location of the word 'only'

Formatted: Font: Bold

762 might be reduced in imminent or future pregnancies. The permanency of lifestyle changes made

763 while attempting fertility might also be established, as well as their impact on family members,

764 and the maintenance of weight loss in the long term. ~~The role of epigenetic changes might also~~

765 ~~be explored~~ (**AUTHOR**: although important, and you are discussing possible future research

766 here, this subject has not been mentioned so far and seems a little unrelated to the overall

767 approach here. It is also unclear what particular studies you would perform, therefore I suggest

768 removing it, which would not detract from the discussion. If you agree, please edit accordingly?

769 Thank you.)~~.~~

770

771 ***Conclusions***

772

773 Non-surgical weight reduction strategies in the infertile have been shown to improve

774 reproductive outcomes in both men and women. Diet, exercise, a combination of the two,

775 weight-loss medication and motivational interviewing have all been efficacious in reducing

776 obesity. In women, weight loss from diet and exercise is associated with improved chances of

777 becoming pregnant, with a trend toward improved live birth rate. Ovulation and menstrual

778 irregularity are also aided. At present there appears to be no significant difference between

779 weight loss interventions and control interventions with respect to rates of miscarriage and IVF

780 conceptions. Well-designed RCTs should also shed light on the effect of weight loss on numbers

781 of oocytes retrieved and other parameters in IVF cycles, and on TTC, as well as the role of

782 interventions in couples. In men, improvements in sperm concentrations, motility and normal

783 morphology have been suggested, as well as in sperm DNA integrity, but further high quality

784 research is needed to confirm these findings and demonstrate improvement in live birth rates in

785 their partners.

Formatted: Font: Bold

Commented [BDA18]: Removed reference to epigenetic studies.

803

804 *References*

805   Anonymous . National Collaborating Centre for Women's and Children's Health (UK). Ectopic
806   Pregnancy and Miscarriage. 2012. RCOG.

807   Aliyeva EA, Fanchenko ND, Parshutin NP, Gasparov AS, Pshenichnikova TI. The effect of a
808   decrease in body weight in patients with the polycystic ovary syndrome. *Akush Ginekol* 1993:**3**; 33-
809   36.

810   Balen A, Dresner M, Scott E, Drife J. Should obese women with polycystic ovary syndrome receive
811   treatment for infertility? *BMJ* 2006a:**332**; 434-435.

812   Balen A, Platteau P, Andersen A, Devroey P, Sorensen P, Helmgaard L, Arce C. The influence of
813   body weight on response to ovulation induction with gonadotrophins in 335 women with World
814   Health Organization group II anovulatory infertility. *BJOG* 2006b:**10**; 1195-1202.

815   Becker GF, Passos EP, Moulin CC. Short-term effects of a hypocaloric diet with low glycemic index
816   and low glycemic load on body adiposity, metabolic variables, ghrelin, leptin, and pregnancy rate in
817   overweight and obese infertile women: a randomized controlled trial. *Am J Clin Nutr* 2015:**6**; 1365-
818   1372.

819   Bellver J, Ayllon Y, Ferrando M, Melo M, Goyri E, Pellicer A, Remohi J, Meseqeur M. Female
820   obesity impairs in vitro fertilization outcome without affecting embryo quality. *Fertil Steril* 2010:**93**;
821   447-454.

822   Bellver J, Martinez-Conejero JA, Labarta E, Alama P, Melo A M, Remohi J, Pellicer A, Horcajadas A
823   J. Endometrial gene expression in the window of implantation is altered in obese women especially in
824   association with polycystic ovary syndrome. *Fertil Steril* 2011:**95**; 2335-2341.

825   Carrell DT, Jones KP, Peterson CM, Aoki V, Emery R B, Campbell R B. Body mass index is
826   inversely related to intrafollicular hCG concentrations, embryo quality and IVF outcome. *Reprod*
827   *Biomed Online* 2001:**2**; 109-111.

828   Chavarro J, Ehrlich S, Colaci D, Wright D, Toth T, Petrozza J, Hauser R. Body mass index and short
829   term weight change in relation to treatment outcomes in women undergoing assisted reproduction.
830   *Fertil Steril* 2012:**1**; 109-116.

831   Clark AM, Thornley B, Tomlinson L, Galletley C, Norman RJ. Weight loss in obese infertile women
832   results in improvement in reproductive outcome for all forms of fertility treatment. *Hum Reprod*
833   1998:**6**; 1502-1505.

834   Clark A, Ledger W, Galletly C, Tomlinson L, Blaney F, Wang X, Norman R. Weight loss results in
835   significant improvement in pregnancy and ovulation rates in anovulatory obese women. *Hum Reprod*
836   1995:**10**; 2705-2712.

837   Crosignani PG, Colombo M, Vegetti W, Somigliana E, Gessati A, Ragni G. Overweight and obese
838   anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices,
839   ovarian physiology and fertility rate induced by diet. *Hum Reprod* 2003:**9**; 1928-1932.

840   Department of Veterans Affairs. VA/DoD clinical practice guideline for screening and management
841   of overweight and obesity. 2014.

842   Dickey RP, Taylor SN, Curole DN, Rye H P, Lu Y P, Pyrzak R. Relationship of clomiphene dose and
843   patient weight to successful treatment. *Hum Reprod* 1997:**12**; 449-453.

844 Dietz WH, Baur LA, Hall K, Puhl RM, Taveras EM, Uauy R, Kopelman P. Management of obesity:
845 improvement of health-care training and systems for prevention and care. *Lancet* 2015:**9986**; 2521-
846 2533.

847 Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological
848 quality both of randomised and non-randomised studies of health care interventions. *J Epidemiol*
849 *Community Health* 1998:**6**; 377-384.

850 Duval K, Belan M, JeanDenis F, Baillargeon J. An interdisciplinary lifestyle intervention improves
851 clinically relevant fertility outcomes in obese infertile women-preliminary results. *Fertil Steril*
852 2015a:**3 SUPPL. 1**; e97.

853 Duval K, Langlois M, Carranza-Mamane B, Pesant M, Hivert M, Poder TG, Lavoie HB, Ainmelk Y,
854 St-Cyr Tribble D, Laredo S et al. The Obesity-Fertility Protocol: a randomized controlled trial
855 assessing clinical outcomes and costs of a transferable interdisciplinary lifestyle intervention, before
856 and during pregnancy, in obese infertile women. *BMC Obesity* 2015b:**2**; 47.

857 ESHRE TR, Group, ASRM-Sponsored PCOS Consensus Workshop. Revised 2003 consensus on
858 diagnostic criteria and long-term health risks related to polycystic ovary syndrome. *Fertil Steril*
859 2004:**1**; 19-25.

860 Farquhar C, Gillett W. Prioritising for fertility treatments?should a high BMI exclude treatment?
861 *BJOG* 2006:**10**; 1107-1109.

862 Faure C, Dupont C, Baraibar MA, Ladouce R, Cedrin-Durnerin I, Wolf JP, Lévy R. In subfertile
863 couple, abdominal fat loss in men is associated with improvement of sperm quality and pregnancy: a
864 case-series. *PLoS ONE* 2014:**2**; e86300.

865 Ferlitsch K, Sator O M, Gruber M D. Body mass index, follicle stimulating hormone and their
866 predictive value in in vitro fertilization. *J Assist Reprod Genet* 2004:**21**; 431-436.

867 Galletly C, Clark A, Tomlinson L, Blaney F. A group program for obese, infertile women: Weight
868 loss and improved psychological health. *J Psychosom Obstet Gynaecol* 1996:**2**; 125-128.

869 Gesink Law DC, Maclehose RF, Longnecker MP. Obesity and time to pregnancy. *Hum Reprod*
870 2006:**22**; 414-420.

871 Hakonsen L, Thulstrup A, Aggerholm A, Olsen J, Bonde J, Andersen C, Bungum M, Ernst E, Hansen
872 M, Ernst E et al. Does weight loss improve semen quality and reproductive hormones? Results from a
873 cohort of severely obese men. *Reprod Health* 2011:**1**; 24.

874 Hammiche F, Laven JSE, Twigt JM, Boellaard WPA, Steegers EAP, SteegersTheunissen RP. Body
875 mass index and central adiposity are associated with sperm quality in men of subfertile couples. *Hum*
876 *Reprod* 2012:**8**; 2365-2372.

877 Hammoud A, Meikle A, Reis L, Gibson M, Peterson C, Carrell D. Obesity and Male Infertility: A
878 Practical Approach. *Semin Reprod Med* 2012:**6**; 486-495.

879 Hartz A, Barboriak P, Wong A, Katayama K, Rimm A. The association of obesity with infertility and
880 related menstrual abnormalities in women. *Int J Obes* 1979:**1**; 57-73.

881 Hauner H, Petzinna D, Sommerauer B, Toplak H. Effect of acarbose on weight maintenance after
882 dietary weight loss in obese subjects. *Diabetes Obes Metab* 2001:**6**; 423-427.

883 Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L,
884 Sterne JA et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*
885 2011:**343**; d5928.

886 Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002:**11**; 1539-
887 1558.

888 Homan G, Litt J, Norman RJ. The FAST study: Fertility ASsessment and advice Targeting lifestyle
889 choices and behaviours: A pilot study. *Hum Reprod* 2012:**8**; 2396-2404.

890 Infertility Network UK. NHS Funding for Fertility Treatment in Scotland. 2015: **October**.

891 Johns DJ, Hartmann-Boyce J, Jebb SA, Aveyard P, on behalf of the Behavioural Weight Management
892 Review Group. Weight change among people randomized to minimal intervention control groups in
893 weight loss trials. 2016:**4**; 772-780.

894 Källén BA. Antiobesity drugs in early pregnancy and congenital malformations in the offspring.
895 2014:**6**; e571-e576.

896 Karimzadeh MA, Javedani M. An assessment of lifestyle modification versus medical treatment with
897 clomiphene citrate, metformin, and clomiphene citrate-metformin in patients with polycystic ovary
898 syndrome. *Fertil Steril* 2010:**1**; 216-220.

899 Karlsen K, Humaidan P, Sorensen LH, Alsbjerg B, Ravn P. Motivational interviewing: A part of the
900 weight loss program for overweight and obese women prior to fertility treatment. *Gynecol Endocrinol*
901 2013:**9**; 839-842.

902 Keltz J, Zapantis A, Jindal S, Lieman H, Santoro N, Polotsky A. Overweight Men: Clinical pregnancy
903 after ART is decreased in IVF but not in ICSI cycles. *J Assist Reprod Genet* 2010:**9-10**; 539-544.

904 Khan KS, Ter Riet G, Glanville J, Sowden AJ, Kleijnen J. Undertaking systematic reviews of research
905 on effectiveness: CRD's guidance for carrying out or commissioning reviews. 2001. NHS Centre for
906 Reviews and Dissemination.

907 Khaskheli M, Baloch S, Baloch AS. Infertility and weight reduction: Influence and outcome. *J
908 College Phys Surg Pak* 2013:**23**; 798-801.

909 Klenov V, Jungheim E. Obesity and reproductive function: a review of the evidence. *Curr Opin
910 Obstet Gynecol* 2014:**26**; 455-460.

911 Koning AMH. Fertility treatment in obese women. *Thesis* 2015:.

912 Kort J, Kim S, Lathi R. A Cohort Study to Evaluate the Impact of Weight Loss on Fertility Outcomes
913 in an Overweight/obese Population. *Fertil Steril* 2013:**3**; S4.

914 Kort J, Winget C, Kim S, Lathi R. A retrospective cohort study to evaluate the impact of meaningful
915 weight loss on fertility outcomes in an overweight population with infertility. *Fertil Steril* 2014:**5**;
916 1400-1403.

917 Kumar P, Arora S. Orlistat in polycystic ovarian syndrome reduces weight with improvement in lipid
918 profile and pregnancy rates. *J Hum Reprod Sci* 2014:**4**; 255-261.

919 Lazurova I, Dravecka I, Kraus V, Petrovicova J. Metformin versus sibutramine in the treatment of
920 hyperinsulinemia in chronically anovulating women. *Bratisl Lek Listy* 2004:**5-6**; 207-210.

921 Legro RS, Dodson WC, KrisEtherton PM, Kunselman AR, Stetter CM, Williams NI, Gnatuk CL,
922 Estes SJ, Fleming J, Allison KC et al. Randomized controlled trial of preconception interventions in
923 infertile women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 2015:**11**; 4048-4058.

924 Maheshwari A, Stofberg L, Bhattacharya S. Effect of overweight and obesity on assisted reproductive
925 technology - a systematic review. *Hum Reprod Update* 2007:**5**; 433-444.

926 Mahoney D. Lifestyle modification intervention among infertile overweight and obese women with
927 polycystic ovary syndrome. *J Am Assoc Nurse Pract* 2014:**6**; 301-308.

928 Mavropoulos JC, Yancy WS, Hepburn J, Westman EC. The effects of a low-carbohydrate, ketogenic
929 diet on the polycystic ovary syndrome: A pilot study. *Nutr Metab* 2005:**1**; 35.

930 Metwally M, Cutting R, Tipton A, Skull J, Ledger L W, Li C T. Effect of increased body mass index
931 on oocyte and embryo quality in IVF patients. *Reprod Biomed Online* 2007:**5**; 532-538.

932 Moran L, Noakes M, Clifton P, Tomlinson L, Norman R. Dietary composition in restoring
933 reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. *J Clin
934 Endocrinol Metab* 2003:**2**; 812-819.

935 Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary
936 syndrome. *Cochrane Database Syst Rev* 2011a; 007506.

937 Moran L, Tsagareli V, Norman R, Noakes M. Diet and IVF pilot study: Short-term weight loss
938 improves pregnancy rates in overweight/obese women undertaking IVF. *Aust N Z J Obstet Gynaecol*
939 2011b:**51**; 455-459.

940 Mutsaerts MAQ, Van Oers AM, Groen H, Burggraaff JM, Kuchenbecker WKH, Perquin DAM, Koks
941 CAM, Van Golde R, Kaaijk EM, Schierbeek JM et al. Randomized trial of a lifestyle program in
942 obese infertile women. *N Engl J Med* 2016:**20**; 1942-1953.

943 National Clinical Guideline Centre. Obesity: Identification and management of overweight and
944 obesity in children, young people and adults. Commissioned by the National Institute for Health and
945 Care Excellence. 2014; 1.

946 National Institute for Health and Clinical Excellence. CG156 Fertility: Assessment and treatment for
947 people with fertility problems. 2013.

948 North American Association for the Study of Obesity, National Heart, Blood Institute, National
949 Institutes of Health (US), NHLBI Obesity Education Initiative. The practical guide: identification,
950 evaluation, and treatment of overweight and obesity in adults. 2000. National Institutes of Health,
951 National Heart, Lung, and Blood Institute, NHLBI Obesity Education Initiative, North American
952 Association for the Study of Obesity.

953 Palomba S, Falbo A, Giallauria F, Russo T, Rocca M, Tolino A, Zullo F, Orio F. Six weeks of
954 structured exercise training and hypocaloric diet increases the probability of ovulation after
955 clomiphene citrate in overweight and obese patients with polycystic ovary syndrome: A randomized
956 controlled trial. *Hum Reprod* 2010:**11**; 2783-2791.

957 Palomba S, Giallauria F, Falbo A, Russo T, Oppedisano R, Tolino A, Colao A, Vigorito C, Zullo F,
958 Orio F. Structured exercise training programme versus hypocaloric hyperproteic diet in obese
959 polycystic ovary syndrome patients with anovulatory infertility: A 24-week pilot study. *Hum Reprod*
960 2008:**3**; 642-650.

961 Qublan HS, Yannakoula EK, Al-Qudad MA, El-Uri FI. Dietary intervention versus metformin to
962 improve the reproductive outcome in women with polycystic ovary syndrome. A prospective
963 comparative study. *Saudi Med J* 2007:**11**; 1694-1698.

964 Ramlau-Hansen H, Thulstrup M, Nohr A, Bonde P, Sørensen I, Olsen J. Subfecundity in overweight
965 and obese couples. *Hum Reprod* 2007:**6**; 1634-1637.

966 Sallmen M, Sandler DP, Hoppin JA, Blair A, Baird DD. Reduced fertility among overweight and
967 obese men. *Epidemiology* 2006:**5**; 520-523.

968 Schneider G, Kirschner A M, Merkowitz R, Ertel H N. Increased estrogen production in obese men. *J
969 Clin Endocrinol Metab* 1979:**4**; 633-638.

970 Sermondade N, Faure C, Fezeu L, Shayeb G A, Bonde P J, Jensen T, Van Wely M, Cao J, Martini C
971 A, Eskandar M et al. BMI in relation to sperm count: an updated systematic review and collaborative
972 meta-analysis. *Hum Reprod Update* 2013:**3**; 221-231.

973 Shukla K, Chambial S, Dwivedi S, Misra S, Sharma P. Recent scenario of obesity and male fertility.
974 *Andrology* 2014:**6**; 809-818.

975 Sim KA, Dezarnaulds GM, Denyer GS, Skilton MR, Caterson ID. Weight loss improves reproductive
976 outcomes in obese women undergoing fertility treatment: A randomized controlled trial. *Clin Obes*
977 2014a:**2**; 61-68.

978 Sim KA, Partridge SR, Sainsbury A. Does weight loss in overweight or obese women improve
979 fertility treatment outcomes? A systematic review. *Obes Rev* 2014b:**10**; 839-850.

980 Styne-Gross A, Elkind-Hirsch K, Scott Jr T R. Obesity does not impact implantation rates or
981 pregnancy outcome in women attempting conception through oocyte donation. *Fertil Steril* 2005:**83**;
982 1629-1634.

983 The Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Ovarian
984 stimulation in assisted reproduction. 2011; 1.

985 Thoma ME, McLain AC, Louis JF, King RB, Trumble AC, Sundaram R, Louis GMB. Prevalence of
986 infertility in the United States as estimated by the current duration approach and a traditional
987 constructed approach. *Fertil Steril* 2013:**5**; 1324-1331. e1.

988 Thomson RL, Buckley JD, Brinkworth GD. Perceived exercise barriers are reduced and benefits are
989 improved with lifestyle modification in overweight and obese women with polycystic ovary
990 syndrome: a randomised controlled trial. *BMC Womens Health* 2016:**1**; 1.

991 Thomson RL, Buckley JD, Moran LJ, Noakes M, Clifton PM, Norman RJ, Brinkworth GD. The
992 effect of weight loss on anti-Mullerian hormone levels in overweight and obese women with
993 polycystic ovary syndrome and reproductive impairment. *Hum Reprod* 2009:**8**; 1976-1981.

994 Thomson RL, Buckley JD, Noakes M, Clifton PM, Norman RJ, Brinkworth GD. The effect of a
995 hypocaloric diet with and without exercise training on body composition, cardiometabolic risk profile,

996 and reproductive function in overweight and obese women with polycystic ovary syndrome. *J Clin*
997 *Endocrinol Metab* 2008:**9**; 3373-3380.

998 Turner-McGrievy GM, Davidson CR, Wingard EE, Billings DL. Low glycemic index vegan or low-
999 calorie weight loss diets for women with polycystic ovary syndrome: A randomized controlled
1000 feasibility study. *Nutr Res* 2014:**6**; 552-558.

1001 Umul M, Kose S, Bilen E, Altuncu AG, Oksay T, Guney M. Effect of increasing paternal body mass
1002 index on pregnancy and live birth rates in couples undergoing intracytoplasmic sperm injection.
1003 *Andrologia* 2015:**3**; 360-364.

1004 Vahratian A, Smith YR. Should access to fertility-related services be conditional on body mass index?
1005 *Hum Reprod* 2009:**7**; 1532-1537.

1006 van Dam EWCM, Roelfsema F, Veldhuis JD, Hogendoorn S, Westenberg J, Helmerhorst FM, Frölich
1007 M, Krans HMJ, Meinders AE, Pijl H. Retention of estradiol negative feedback relationship to LH
1008 predicts ovulation in response to caloric restriction and weight loss in obese patients with polycystic
1009 ovary syndrome. *Am J Physiol Endocrinol Metab* 2004:**4**; E615-E620.

1010 Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, Bouter LM, Knipschild PG. The Delphi
1011 list: a criteria list for quality assessment of randomized clinical trials for conducting systematic
1012 reviews developed by Delphi consensus. *J Clin Epidemiol* 1998:**12**; 1235-1241.

1013 Waters L, George AS, Chey T, Bauman A. Weight change in control group participants in
1014 behavioural weight loss interventions: a systematic review and meta-regression study. 2012:**1**; 120.

1015 Wise L, Palmer J, Rosenberg L. Body size and time-to-pregnancy in black women. *Hum Reprod*
1016 2013:**10**; 2856-2864.

1017 Wise L, Rothman K, Mikkelsen E, Sorensen H, Riis A, Hatch E. An internet-based prospective study
1018 of body size and time-to-pregnancy. *Hum Reprod* 2010:**1**; 253-264.

1019 World Health Organization. Obesity and Overweight fact sheet no 311. 2016: **April 17**.

1020 Zain M, Norman R. Impact of obesity on female fertility and fertility treatment. *Womens Health*
1021 *(Lond)* 2008:**2**; 183-194.

1022 Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational
1023 approach. In Dunaif A, Givens JR, Haseltine FP and Merriam GR (eds) Polycystic ovary syndrome.
1024 1992. Blackwell Scientific Publications, Boston, pp. 377-384.

1025 Zegers-Hochschild F, Adamson GD, de Mouzon J, Ishihara O, Mansour R, Nygren K, Sullivan E, van
1026 der Poel S, International Committee for Monitoring Assisted Reproductive Technology, World Health
1027 Organization. The International Committee for Monitoring Assisted Reproductive Technology
1028 (ICMART) and the World Health Organization (WHO) Revised Glossary on ART Terminology,
1029 2009. *Hum Reprod* 2009:**11**; 2683-2687.

1030

1031

1032

Figure legends

AUTHOR: I have files for a Figure 1 (PRISMA chart in tiff format) plus Figures 2-14 in eps format. The legends below are for only 13 figures. Please would you recheck the figure numbering/titles?

Figure 1. PRISMA flow diagram illustrating the process of selection of studies for inclusion in the systematic review. AUTHOR: please would you provide a higher quality image for Production?

Figure 2. AUTHOR: it may be helpful to also state in all titles that these are Forest plots. Forest plot - Pregnancies associated with diet, diet and exercise, orlistat and motivational interviewing versus control.

Figure 3. Forest plot - Intervention versus control: live births.

Figure 4. Forest plot - Intervention versus control: spontaneous conceptions.

Figure 5. Forest plot - Intervention versus control: IVF conceptions.

Figure 6. Forest plot - Intervention versus control: miscarriages for all participants enrolled.

Figure 7. Forest plot - Intervention versus control: miscarriages for women who became pregnant.

Figure 8. Forest plot - Intervention versus control: ovulation improvement.

Figure 9. Forest plot - Intervention versus control: improvement of menstrual irregularity.

Figure 10. Forest plot - Intervention versus control: oocytes retrieved per female participant.

Figure 11. Forest plot - Intervention versus control: change in weight (kg).

Figure 12. Forest plot - Intervention versus metformin: women who became pregnant.

Figure 13. Forest plot - Intervention versus metformin: improvement in ovulation.

Figure 14. Forest plot – Intervention versus metformin: improvement in menstrual irregularity per irregular menstruating female participant

AUTHOR: we tend not to include Appendices, therefore these data have been divided and renamed as supplementary files. The quality of the file for the

40

1061 Supplementary Data (search strategy) is not high enough for Production, therefore
1062 please would you send to me a high quality file, eps or tiff format, and preferably at
1063 300dpi? Word and Powerpoint are acceptable if not pixelated or blurry at 400%. Thank
1064 you.
1065

1066

1067

> **Commented [BDA22]:** I can sent the original .txt file, which should solve the problems with the image

1068

1069

Table 1. Types of interventions evaluated in studies of weight loss interventions and fertility in women and men who are overweight or obese.

Reducing diet/healthy eating and exercise programme or advice	
Duval *et al* 2015 G	RCT
Karimzadeh *et al* 2010	RCT
Moran *et al* 2011	RCT
Mutsaerts *et al* 2016	RCT
Palomba *et al* 2010 G	RCT
Sim *et al* 2014 G	RCT
Clark *et al* 1998 G	Non-RCT
Crosignani *et al* 2003	Cohort
De Frène 2015	Cohort
Faure *et al* 2014	Cohort
Galletly *et al* 1996a G	Cohort
Galletly *et al* 1996b G	Cohort
Hakonsen *et al* 2011	Cohort
Hollman *et al* 1996	Cohort
Khaskheli *et al* 2013	Cohort
Mahoney *et al* 2014	Cohort
Miller *et al* 2008 G	Cohort
Salama *et al* 2015	Cohort
Reducing diet/healthy eating, weight loss drugs, and exercise programme or advice	
Legro *et al* 2015	RCT
Lazurova *et al* 2004	Non-RCT
Kort *et al* 2014	Cohort
Reducing diet/health eating, or type of diet	

Formatted: Font: Not Bold
Formatted: Font: Not Bold, Italic
Formatted: Font: Not Bold
Formatted: Font: 12 pt, Bold

~~Becker~~Becker *et al* 2015	RCT
~~Moran~~Moran *et al* 2003	RCT
~~Qublan~~Qublan *et al* 2007	RCT
~~Turner-McGrievy~~Turner-McGrievy *et al* 2014	RCT
~~Aliyeva~~Aliyeva *et al* 1993	Non-RCT
~~Palomba~~Palomba *et al* 2008 G	Non-RCT
~~Awartani~~Awartani *et al* 2012	Cohort
~~Kiddy~~Kiddy *et al* 1992	Cohort
~~Mavropoulos~~Mavropoulos *et al* 2005 G	Cohort
~~Thomson~~Thomson *et al* 2009	Cohort
~~Tsagareli~~Tsagareli *et al* 2006	Cohort
~~Van Dam~~Van Dam *et al* 2004	Cohort
Behavioural therapy, including motivational interviewing	
~~Karlsen~~Karlsen *et al* 2013	Non-RCT
~~Koning~~Koning *et al* 2015 C	Non-RCT
~~Homan~~Homan *et al* 2012	Cohort
Exercise programme	
~~Thomson~~Thomson *et al* 2008 G	RCT
~~Palomba~~Palomba *et al* 2008	Non-RCT
Orlistat	
~~Kumar~~Kumar *et al* 2014	RCT
Metformin	
~~Karimzadeh~~Karimzadeh *et al* 2010	RCT
~~Kumar~~Kumar *et al* 2014	RCT
~~Qublan~~Qublan *et al* 2007	RCT
~~Sonmez~~Sonmez *et al* 2005	RCT
~~Lazurova~~Lazurova *et al* 2004	Non-RCT
Acarbose	
~~Sonmez~~Sonmez *et al* 2005	RCT
Detailed lifestyle questionnaire	

G, group intervention; C, couples were able to take part

Table 2. Reproductive outcomes for women (lower numbers for ranking indicate better outcomes).

Study ID	Intervention arm	N	Pregnancies per participant		% Live births per participant		% Miscarriages per participant (fewer = better)		% Miscarriages per pregnancy (fewer = better)		% Improved ovulation per anovulatory participant		% Improved menstrual irregularity / irregular menses per participant		Time to conception per participant (less = better)	
			Rank	%	Rank	%	Rank	%	Rank	%	Rank	%	Rank	%	Rank	
DuvalDuval *et al* 2015	Diet & exercise	24	1	79.2	2	62.5										
ClarkClark *et al* 1998	Diet & exercise	67	2	77.6	1	67.2	13	14.9	9	18.2	1	89.6				
KortKort *et al* 2014	Diet & exercise	52	3	65.4	4	48.1									4	226.57 days for those with 10&% weight loss
MutsaertsMutsaerts *et al* 2016	Diet & exercise	280	4	63.9	3	53.2	12	14.6	12	22.9	17	42.4			3	Median 7.2 months (IQR 2.6, 12.0)
KhaskheliKhaskheli *et al* 2013	Diet & exercise	85	5	63.5	8	37.6	11	10.6	7	16.7						
GalletlyGalletly *et al* 1996(b)	Diet & exercise	58	6	58.6												
MoranMoran *et al* 2011	Diet & exercise	18	7	57.1	7	38.9										
KoningKoning *et al* 2015	Motivational interviewing	102	8	53.9	5	47.1	2	2.0	2	3.6						
ChavarroChavarro *et al* 2012	Questionnaire	170	9	51.2												
AliyevaAliyeva *et al* 1993	Acupuncture	20	10	45.0							9	55.0	15	45.0		
SimSim *et al* 2014	Diet & exercise	26	11	44.4	6	44.4	14	18.5	14	41.7						
KumarKumar *et al* 2014	Orlistat	30	11	40.0							10	50.0				
MavropoulosMavropoulos *et al* 2005	Low calorie ketogenic diet	5	13	40.0												

Study ID	Intervention arm		Pregnancies per participant		% Live births per participant		% Miscarriages per participant (fewer = better)		% Miscarriages per pregnancy (fewer = better)		% Improved ovulation per anovulatory participant		% Improved menstrual irregularity / irregular menses per participant		Time to conception per participant (less = better)
		N	Rank	%	Rank	%	Rank	%	Rank	%	Rank	%	Rank	%	Rank
Palomba et al 2008	Exercise	20	14	35.0			7	5.0	5	14.3	5	65.0			
Homan et al 2012	Motivational interviewing	35	15	34.8			5	4.3	3	12.5					
Awartani et al 2012	Weight reduction advised	90	16	34.4											
Qublan et al 2007	Diet	24	17	33.3			4	4.2	3	12.5	10	50.0	11	61.9	
Legro et al 2015	Diet & exercise	50	18	32.0	9	26.0	9	6.0	10	18.8	6	60.3			
Crosignani et al 2003	Diet & exercise	33	19	30.3	10	24.2					8	55.6	6	66.7	
Aliyeva et al 1993	Diet	60	20	30.0							14	46.7	8	63.3	
Kiddy et al 1992	Very low calorie diet/Low calorie diet	24	21	29.2	14	16.7	10	8.3	13	28.6			20	29.4	
Hollman et al 1996	Diet & exercise	35	22	28.6	12	22.9	8	5.7	11	20.0			3	80.0	
Legro et al 2015	Diet, exercise, oral contraceptive pill	50	23	28.0	11	24.0	3	4.0	5	14.3	4	67.1			
Qublan et al 2007	Metformin	22	24	27.3			6	4.5	7	16.7	15	45.5	12	61.1	
Kumar et al 2014	Metformin	30	25	26.7							20	23.3			
Becker et al 2015	Diet	14	26	21.4	13	21.4									
Karimzadeh et al 2010	Diet & exercise	75	26	20.0									6	66.7	
Lazurova et al 2004	Metformin	30	28	20.0									4	70.0	
Miller et al 2008	Diet & exercise	12	29	16.7									1	83.3	
Karimzadeh et al 2010	Metformin & clomiphene	88	30	14.8									10	62.5	
DeFrene 2015	Diet & exercise	23	31	13.0											
Karimzadeh et al 2010	Metformin	90	32	12.2									13	55.6	
Salama et al 2015	Mediterranean diet & exercise	58	33	12.1									9	62.8	

Study ID	Intervention arm		Pregnancies per participant		% Live births per participant		% Miscarriages per participant (fewer = better)		% Miscarriages per pregnancy (fewer = better)		% Improved ovulation per anovulatory participant		% Improved menstrual irregularity / irregular menses per participant		Time to conception per participant (less = better)	
		N	Rank	%	Rank	%	Rank	%	Rank	%	Rank	%	Rank	%	Rank	
Turner-McGrievy et al 2014	Low calorie diet	9	34	11.1							22	0.0				
Palomba et al 2008	Diet	20	35	10.0			1	0.0	1	0.0	19	25.0				
Galletly et al 1996(a)	Exercise & advice	96	36	9.4												
Moran et al 2003	High protein diet	14	37	8.7									21	26.1	1	4-5 weeks
Lazurova et al 2004	Sibutramine, diet, exercise	15	38	6.7									14	53.3		
Thomson et al 2008	Diet & aerobic exercise	31	39	6.3							10	50.0	17	42.9		
Moran et al 2003	Low protein diet	14	40	4.3									22	22.7	1	4-5 weeks
Thomson et al 2008	Diet	30	41	3.3							10	50.0	24	21.4		
Palomba et al 2010	Diet & exercise, Clomiphene	32	42	3.1							18	37.5	19	34.4		
Thomson et al 2008	Diet & aerobic & resistance exercise	33	43	3.0							16	42.8	16	44.4		
Turner McGrievy 2014	Vegan diet	9	44	0							22	0.0				
Sonmez et al 2005	Acarbose	15									2	86.7	5	69.2		
Sonmez et al 2005	Metformin	15									3	80.0	2	80.0		
Van Dam et al 2004	Very low calorie diet	15									6	60.0				
Thomson et al 2009	Diet	52									20	19.2	18	42.3		
Palomba et al 2010	Diet & exercise	32									21	12.5	25	12.5		
Mahoney et al 2014	Motivational interviewing, diet, exercise												23	22.2		

Table 3. Weight reduction outcomes for women (lower numbers for ranking indicate better outcomes).

Study ID	Intervention Arm		Mean Weight change (kg) Per Participant		Mean BMI change (kg/m^2) Per Participant		Mean Waist Circumference change (cm) Per Participant	
		N	Rank	Change	Rank	Change	Rank	Change
~~Mavropoulos~~Mavropoulos *et al* 2005	Low calorie ketogenic diet	5	1	-12.34 ± 6.37	8	-4.0		
~~Hollman~~Hollman *et al* 1996	Diet & exercise	35	2	-10.2 ± 7.9	10	-3.4 (median)		
~~Clark~~Clark *et al* 1998	Diet & exercise	67	3	-10.2 ± 4.3	9	-3.7 ± 1.6		
~~Thomson~~Thomson *et al* 2008	Diet & aerobic exercise	31	4	-10.1 ± 5.6			1	-11.7 ± 6.1
~~Karlsen~~Karlsen *et al* 2013	Motivational interviewing	110	5	-9.3	11	-3.3		
~~Thomson~~Thomson *et al* 2009	Diet	52	6	-9.0 ± 0.8 (SEM)			4	-10.4 ± 0.9 (SEM)
~~Thomson~~Thomson *et al* 2008	Diet	30	7	-8.6 ± 6.0			3	-10.8 ± 7.1
~~Thomson~~Thomson *et al* 2008	Diet & aerobic & resistance exercise	3	8	-8.6 ± 5.2			2	-11.0 ± 6.3
~~Moran~~Moran *et al* 2003	High protein diet	14	9	-8.5 ± 1.1				
~~Kumar~~Kumar *et al* 2014	Orlistat	30	10	-7.81 ± 0.66%	4	-8.12 ± 6.71%		
~~Kumar~~Kumar *et al* 2014	Metformin	30	11	-7.78 ± 0.57% (SEM)	3	-8.40 ± 0.65% (SEM)	14	-2.68 ± 0.16% (SEM)
~~Kiddy~~Kiddy *et al* 1992	Very low calorie diet/low calorie diet	24	12	-6.9 ± 6.7				
~~Moran~~Moran *et al* 2003	Low protein diet	14	13	-6.9 ± 0.8 (SEM)				
~~Sim~~Sim *et al* 2014	Diet & exercise	26	14	-6.6 ± 4.6	14	-2.4 ± 1.6	6	-8.7 ± 5.6
~~Salama~~Salama *et al* 2015	Mediterranean diet & exercise	58	15	-6.3 ± 20.8	16	-2.37 ± 7.28	7	-6.45 ± 14.13
~~Legro~~Legro *et al* 2015	Lifestyle	50	16	-6.2, 95% CI (-7.3, -5.3)			8	-6.3, 95% CI (-9.2, -3.4)
~~Galletly~~Galletly *et al* 1996(b)	Diet and exercise	58	17	-6.2 ± 4.5	13	-2.4 ± 1.7		
~~Legro~~Legro *et al* 2015	Diet, exercise, oral contraceptive pill	50	18	-6.1, 95% CI (-7.0, -5.2)			9	-6.2, 95% CI (-9.1, -3.3)
~~Tsagareli~~Tsagareli *et al* 2006	Very low calorie diet	6	19	-5.6; Range -8.2 to -5.3	17	-2.1; Range -1.8 to -3.2	5	-10.0; Range -7 to-14
~~Galletly~~Galletly *et al* 1996(a)	Diet & exercise	96	20	-5.2 ± 5.1				
~~Becker~~Becker *et al* 2015	Diet	14	21	-4.51 ± 0.83 (SEM)			15	-1.31 ± 10.5
~~Palomba~~Palomba *et al* 2010	Diet & exercise, Clomiphene	32	22	-4.42 ± 9.22	12	-2.64 ± 4.26	11	-4.92 ± 5.87

Study ID	Intervention Arm		Mean Weight change (kg) Per Participant		Mean BMI change (kg/m²) Per Participant		Mean Waist Circumference change (cm) Per Participant	
		N	Rank	Change	Rank	Change	Rank	Change
~~Mutsaerts~~Mutsaerts *et al* 2016	Diet & exercise	280	23	-4.4 ± 5.8	21	-1.3 (Median) IQR (-2.5, -0.07)		
~~Koning~~Koning *et al* 2015	Motivational interviewing	102	24	-4.3 ± 0.8 (SEM)	20	-1.4 ± 0.3 (SEM)		
~~Palomba~~Palomba *et al* 2010	Diet & exercise	32	25	-4.21 ± 8.56	15	-2.39 ± 3.54	12	-3.84 ± 6.35
~~Moran~~Moran *et al* 2011	Diet & exercise	18	26	-3.8 ± 3.0	19	-1.4 ± 1.1	10	-5.3 ± 4.6
~~Mahoney~~Mahoney *et al* 2014	Motivational interviewing, diet, exercise	9	27	-3.18 ± 2.27	24	-0.7 ± 7.31		
~~Turner-McGrievy~~Turner-McGrievy *et al* 2014	Vegan diet	9	28	-2.1 ± 3.5				
~~Turner-McGrievy~~Turner-McGrievy *et al* 2014	Low calorie diet	9	29	-0.4 ± 0.9				
~~Chavarro~~Chavarro *et al* 2012	Questionnaire	170	30	&0.3 (Median) IQR (-0.1, 1.8)				
~~Kort~~Kort *et al* 2014	Diet & exercise	52			1	-13.89% ± 3.71% in 17 with 10&% weight loss -3.79% ± 3.98% in 35 with <10% weight loss		
~~Khaskheli~~Khaskheli *et al* 2013	Diet & exercise	85			2	-9.6 ± 1.23		
~~Lazurova~~Lazurova *et al* 2004	Sibutramine, diet, exercise	15			5	-4.6 ± 4.2 (SEM)		
~~Qublan~~Qublan *et al* 2007	Diet	24			6	-4.8		
~~Qublan~~Qublan *et al* 2007	Metformin	22			7	-4.1		
~~Miller~~Miller *et al* 2008	Diet & exercise	12			18	-2.06 ± 0.51 (SEM)		
~~Sonmez~~Sonmez *et al* 2005	Acarbose	15			22	-1.1 ± 2.78		
~~Lazurova~~Lazurova *et al* 2004	Metformin	30			23	-0.85 ± 0.38 (SEM)		
~~Sonmez~~Sonmez *et al* 2005	Metformin	15			25	-0.3 ± 2.47		
~~Homan~~Homan *et al* 2012	Motivational interviewing	35		"47% of the overweight participants had a modest loss of between 1 and 5 kg (not statistically significant)"				-3.8 in ½ of those attending follow-up and not pregnant
~~Duval~~Duval *et al* 2015	Diet & exercise	24		10/24 had ≥ 5% weight loss				12/24 had ≥ 5cm reduction (compared to 11/31 in control group)

Study ID	Intervention Arm		Mean Weight change (kg) Per Participant		Mean BMI change (kg/m²) Per Participant		Mean Waist Circumference change (cm) Per Participant	
		N	Rank	Change	Rank	Change	Rank	Change
				(compared to 11/31 in control group)				
~~Karimzadeh~~Karimzadeh *et al* 2010	Diet & exercise	75						Significantly lower waist circumference (P=0.001) in the lifestyle group than in the clomiphene, metformin, and clomiphene/metformin groups
~~Aliyeva~~Aliyeva *et al* 1993	Diet	60		"30-40% decrease in body weight in 2-4 months"				
~~Aliyeva~~Aliyeva *et al* 1993	Acupuncture	20		"Slower rate and extent of weight reduction: 7-9 months"				
~~Awartani~~Awartani *et al* 2012	Weight reduction advised	90				23/90 reduced their BMI below 35; 65/90 did not		
~~Crosignani~~Crosignani *et al* 2003	Diet & exercise	33						Those with 5% weight loss had mean waist circumference 94 cm, SD 9 Those with 10% weight loss had mean 86, SD 7
~~Van Dam~~Van Dam *et al* 2004	Very low calorie diet	15		14/15 loss at least 10% of body weight				
~~Palomba~~Palomba *et al* 2008	Exercise	20		Ovulatory (n=13): Mean -5.6%, SD 1.6% Anovulatory (n=7): Mean -2.0% ,SD 0.2%		Ovulatory (n=13): Mean -10.0%, SD 3.7% Anovulatory (n=7): Mean -1.4%, SD 2.1%		Ovulatory (n=13): Mean -9.6%, SD 2.1% Anovulatory (n=7): Mean -2.5%, -SD 2.9%
~~Palomba~~Palomba *et al* 2008	Diet	20		Ovulatory (n=5): Mean -10.5%, SD 4.1% Anovulatory (n=15): Mean -2.3%, SD 3.1%		Ovulatory (n=5): Mean -15.4%, SD 3.9% Anovulatory (n = 15): Mean -4.0%, SD 5.2%		Ovulatory (n=5): Mean -9.4%, SD 2.5% Anovulatory (n=15): Mean -2.8%, SD 3.1%

Table 4. Reproductive and weight outcomes for infertile men.

	Faure~~Faure~~ *et al* 2014 N=8	Hakonsen~~Hakonsen~~ *et al* 2011 N=27 of 44 at follow-up
Clinical pregnancy rate	8/8	
Live birth rate	8/8	
Improvement in sperm DNA integrity	6/6 consenting to semen analysis upon completion	
Change in sperm concentration (million/ml) Group 1: Weight loss 3.5-12.1% Group 2: Weight loss 12.2-17.1% Group 3: Weight loss 17.2-25.4%		Group 1 (n=9) Mean -11 95% CI -49, 27 Group 2 (n=9) Mean +19 95% CI -23, 61 Group 3 (n=9) Mean +17 95% CI -24, 58
Change in sperm motility (% motile)		Group 1 (n=8) Mean -2 95% CI -15, 11 Group 2 (n=9) Mean +4 95% CI -10, 18 Group 3 (n=9) Mean +11 95% CI -3, 25
Change in normal sperm morphology (% normal forms)		Group 1 (n=9) Mean 0 95% CI -2, 4 Group 2 (n=9) Mean +1 95% CI -3, 4 Group 3 (n=9) Mean +4 95% CI 1, 7
Change in weight (kg)	Mean -4.40 SD 5.00	Median -22 Range -4 to –39
Change in BMI (kg/m^2)	Mean -1.22 SD 1.38	
Change in Waist circumference (cm)	Mean -8.50 SD 7.89	